Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Martin Reck; Tudor‐Eliade Ciuleanu; Michael Schenker; Stéphanie Bordenave-Juchereau; Manuel Cobo; Óscar Juan; Niels Reinmuth; Eduardo Richardet; Enriqueta Felip; J. Menezes; Ying Cheng; Hideaki Mizutani; Bogdan Żurawski; Aurelia Alexandru; David P. Carbone; Shun Lu; Thomas John; Takekazu Aoyama; Diederik J. Grootendorst; Nan Hu; Laura J. Eccles; Luis Paz‐Ares

doi:10.1016/j.ejca.2024.114296

Abstract

We report 5-year efficacy and safety outcomes from CheckMate 9LA in patients with metastatic non-small cell lung cancer (mNSCLC) and exploratory analyses in key patient subgroups.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Reck et al. (2024) studied this question.

synapsesocial.com/papers/68e5b019b6db643587549438 https://doi.org/10.1016/j.ejca.2024.114296

View Full Paper

Ask AI

Bookmark

Share

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Abstract

Discussion

Cite This Study

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading